Search | Clinical Trials Finder

Conditions: Musculoskeletal Physiology, Healthy
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cortisol Resistance, Negative Feedback, ACTH, Mineralcorticoid, Glucocorticoid
Interventions: Mifepristone, Placebo, Spironolactone, Combined, Dexamethasone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: 0.1 mg PF-04995274, 1 mg PF-04995274, 10 mg PF-04995274, 15 mg PF-04995274, 1.0 mg PF-04995274; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 2
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Topcon Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 6
States / cities: La Jolla, California • Overland Park, Kansas • New York, New York + 1 more

Conditions: Epstein-Barr Virus Infection
Interventions: mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 482 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 34
States / cities: Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more

Conditions: Healthy Participants
Interventions: Atazanavir/Cobicistat, Reyataz Atazanavir, Cobicistat; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cytomegalovirus
Interventions: mRNA-1647, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 9 Years to 25 Years
Enrollment: 873 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 44
States / cities: La Mesa, California • Sacramento, California • Fort Collins, Colorado + 38 more

Conditions: Cough
Interventions: Camlipixant; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Meningococcal Vaccine
Interventions: rLP2086, Havrix (HAV), Saline; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 3,596 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 62
States / cities: Birmingham, Alabama • Dothan, Alabama • Harrisburg, Arkansas + 42 more

Conditions: Assessment of Hip Strength, Range of Motion, EMG Activation, and Landing Mechanics in Healthy Subjects, Healthy Adult Subjects
Interventions: Hip Bump Manipulation, Sham (No Treatment); Procedure
Lead sponsor: Dominican University New York; Other
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: Chikungunya
Interventions: VLA1553; Biological
Lead sponsor: Valneva Austria GmbH; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Huntsville, Alabama • Peoria, Illinois

Conditions: Aged
Interventions: Experimental Nutritional Powder Formula, Placebo comparator; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 60 Years to 79 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Pneumococcal Immunization, Healthy Volunteers
Interventions: PCV21 vaccine, 20vPCV licensed vaccine; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 2,195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Fayetteville, Arkansas • Huntington Park, California • Los Angeles, California + 9 more

Conditions: Solid Tumours
Interventions: Selumetinib, Moxifloxacin, selumetinib placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Dengue
Interventions: YF-17D, TDV, Placebo; Biological · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 11
States / cities: Mobile, Alabama • Pomona, California • Meridian, Idaho + 8 more

Conditions: Hepatic Impairment, Healthy
Interventions: ONO-2745 /CNS 7056; Drug
Lead sponsor: Ono Pharma USA Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 3
States / cities: Anaheim, California • Orlando, Florida • South Miami, Florida

Conditions: Kidney Transplant, Immunology, Immunosuppression
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 59 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Solid Tumours
Interventions: selumetinib, itraconazole, fluconazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Meningococcal Immunisation, Healthy Volunteers
Interventions: Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine, Placebo, MenABCYW conjugate vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 1,215 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 46
States / cities: Birmingham, Alabama • Guntersville, Alabama • Tempe, Arizona + 36 more

Conditions: Influenza, Swine-origin A/H1N1 Influenza
Interventions: Monovalent Subvirion A/H1N1 Influenza vaccine, Normal saline solution (placebo); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 9 Years
Enrollment: 474 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 20
States / cities: Miami Beach, Florida • Marietta, Georgia • Woodstock, Georgia + 16 more

Conditions: Healthy Participants, Alzheimer's Disease Dementia
Interventions: Emraclidine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 11
States / cities: Cypress, California • San Diego, California • Hialeah, Florida + 8 more

Conditions: Prostate Cancer
Interventions: lycopene; Dietary Supplement
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years to 45 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: lycopene; Dietary Supplement
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years to 45 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lyme Disease
Interventions: VLA15, Saline; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 5 Years and older
Enrollment: 12,546 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 82
States / cities: Essex, Connecticut • Ledyard Center, Connecticut • New London, Connecticut + 67 more

Search by objective public record fields.

Postural Control in the Elderly

Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

An Age-Stratified Data Collection Study to Establish a Normative Database Using the 3D Optical Coherence Tomography 3D OCT-1000 Mark II

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

Effects of Hip Bump Manipulation Versus Sham Treatment in Healthy Adults

Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers

Evaluation of AN777 on Elderly Subjects During Bed Rest and Recovery

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment

Protective Immunity Project 02

To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years

A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease

Lycopene In Preventing of Prostate Cancer

Lycopene in Preventing Prostate Cancer in Healthy Participants

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)